Market Access News | pharmaphorum

News

NICE declines to look again at depression drug Spravato

Johnson & Johnson has slammed a decision by NICE not to carry out a new appraisal of its antidepressant Spravato, claiming it has “grave concern” about access to new mental health treat

News

UK pharma industry delivers election ‘wish list’

The Association of the British Pharmaceutical Industry (ABPI) is calling on political parties contesting the general election to spell out their plans to nurture and drive growth in t

News

FDA clears Ipsen’s primary biliary cholangitis drug

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Scotland first UK nation to clear Mounjaro use for obesity

Scotland has become the first country in the UK to back NHS use of Eli Lilly’s obesity therapy Mounjaro, clearing it to assist weight management in eligible patients.

News

Close-up view of an actinic keratosis lesion

FDA OKs wider use of Almirall’s actinic keratosis drug

With actinic keratosis (AK) diagnoses on the rise, there is some good news for patients, with the FDA approval of expanded use of Almirall’s topical therapy Klisyri.

NICE declines to look again at depression drug Spravato

UK pharma industry delivers election ‘wish list’

FDA clears Ipsen’s primary biliary cholangitis drug

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Scotland first UK nation to clear Mounjaro use for obesity

FDA OKs wider use of Almirall’s actinic keratosis drug

Amgen's Imdelltra scores again in small cell lung cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks